At the news
? BEARISHIMPACT 7/10 8-K filed Aug 13, 2026 at 08:35 ET
PDS Biotech reported Q2 2026 EPS of -$0.18, a 42.1% miss vs consensus of -$0.13, and announced a strategic refocus to prioritize PDS0301, discontinuing the VERSATILE-003 Phase 3 trial for PDS0101. Cash burned to $5.6M from $21.7M at year-end, with negative working capital of -$5.3M, raising going-concern risk. The pipeline pivot and cash runway depletion are the primary stock-moving events, outweighing the earnings miss for this pre-revenue biotech.
- Net loss of $9.8M ($0.18/share) for Q2 2026 vs $9.4M ($0.21/share) in Q2 2025
- EPS of -$0.18 missed consensus of -$0.13 by 42.1%
- Cash balance fell to $5.6M as of June 30, 2026, from $21.7M at March 31, 2026
- Working capital turned negative to -$5.3M from positive $18.8M at year-end 2025
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access